Cancers, Free Full-Text

As lung cancer has the highest cancer-specific mortality rates worldwide, there is an urgent need for new therapeutic and diagnostic approaches to detect early-stage tumors and to monitor their response to the therapy. In addition to the well-established tissue biopsy analysis, liquid-biopsy-based assays may evolve as an important diagnostic tool. The analysis of circulating tumor DNA (ctDNA) is the most established method, followed by other methods such as the analysis of circulating tumor cells (CTCs), microRNAs (miRNAs), and extracellular vesicles (EVs). Both PCR- and NGS-based assays are used for the mutational assessment of lung cancer, including the most frequent driver mutations. However, ctDNA analysis might also play a role in monitoring the efficacy of immunotherapy and its recent accomplishments in the landscape of state-of-the-art lung cancer therapy. Despite the promising aspects of liquid-biopsy-based assays, there are some limitations regarding their sensitivity (risk of false-negative results) and specificity (interpretation of false-positive results). Hence, further studies are needed to evaluate the usefulness of liquid biopsies for lung cancer. Liquid-biopsy-based assays might be integrated into the diagnostic guidelines for lung cancer as a tool to complement conventional tissue sampling.

HER2 and Response to Paclitaxel in Node-Positive Breast Cancer

Cancers, Free Full-Text

Prostate Cancer.Csv - Colaboratory

Gist Ot Typing Tool Software Free - Colaboratory

Detection of HPV-16 DNA by PCR in histologically cancer free lymph nodes from patients with cervical cancer. - Abstract - Europe PMC

Cancers, Free Full-Text

Predicting peritoneal recurrence and disease-free survival from CT images in gastric cancer with multitask deep learning: a retrospective study - The Lancet Digital Health

Comprehensive Cancer Information - NCI

Adagrasib in Non–Small-Cell Lung Cancer Harboring a KRASG12C Mutation

IJMS, Free Full-Text